Overexpression and/or gene amplification of c-Src and members of the epidermal growth factor receptor (EGFR/ ErbB) family have been implicated in the pathogenesis of breast cancer. Although members of the EGFR family are known to form heterocomplexes with one another, c-Src has also been shown to physically interact with members of this family in breast cancer cell lines and tumors. This paper investigates the role of c-Src in modulating the physical and functional interaction between ErbB2 and ErbB3, two family members that preferentially associate with one another and together exhibit high oncogenic potential. We show that overexpressed wild-type c-Src enhances heterocomplex formation of ErbB2 and ErbB3 that results in increased basal and/or heregulin-induced activation of receptors, and their downstream intracellular effectors. Expression of a kinase-inactive form of c-Src (K À c-Src) or pharmacological inhibition of c-Src by PP2 negatively affects these events. Furthermore, cellular motility and anchorage-independent growth promoted by the ErbB2/ErbB3 heterocomplex are dependent upon c-Src, as demonstrated by the effects of K À c-Src overexpression or treatment with PP2. In contrast to previous studies that defined a role for c-Src downstream of ErbB2/ErbB3, the current work suggests an upstream mechanism, whereby c-Src enhances ErbB2/ErbB3 signaling and biological functions by positively modulating the association between ErbB2 and ErbB3.
Introduction
Activation of epidermal growth factor receptor (EGFR/ ErbB/HER1) family members, which include EGFR/ ErbB1/HER1, ErbB2/HER2, ErbB3/HER3 and ErbB4/ HER4, occurs through homotypic or heterotypic interactions, brought about by receptor overexpression and/or stimulation with extracellular ligands (Di Fiore et al., 1987b; Tzahar et al., 1996) . Although ErbB2 itself does not bind any known ligands, it is recruited as a dimerization partner to other ligand-binding ErbB family members, preferentially complexing with heregulin (HRG)-bound ErbB3 to promote cellular transformation (Holbro et al., 2003) . ErbB2 and ErbB3 are also frequently co-overexpressed in human breast cancer tissues and cell lines (Belsches-Jablonski et al., 2001) . Overexpression of ErbB2 alone or with ErbB3, correlates with hormone-resistant breast cancer and poor prognostic indices (Slamon et al., 1987) . Taken together, these studies indicate that the ErbB2/ErbB3 heterocomplex is a key etiological component of breast cancer and that it is critical to understand its mechanisms of action to aid the design of novel, effective chemotherapeutics.
One factor proposed to promote transduction of signals emanating from the ErbB2/ErbB3 heterocomplex is c-Src, an intracellular tyrosine kinase. Like ErbB family members, elevated protein expression or activity of c-Src has been detected in >70% of human breast cancers (Ottenhoff-Kalff et al., 1992; Belsches-Jablonski et al., 2001) . Because c-Src and ErbB family members are overexpressed together in human breast cancer, the question arises as to whether they functionally interact to facilitate oncogenesis. Previous investigations have demonstrated that c-Src synergizes with the EGFR to promote mitogenic and tumorigenic growth (Ishizawar and Parsons, 2004) , raising the possibility that c-Src may also interact with ErbB2 and/or ErbB3.
In fact, previous studies have shown that c-Src associates with ErbB2 in human breast cancer cells (Muthuswamy et al., 1994; Sheffield, 1998; BelschesJablonski et al., 2001) , an interaction that is dependent upon the tyrosine phosphorylated cytoplasmic and/or kinase domain of ErbB2 and the SH2 domain of c-Src (Kim et al., 2005; Luttrell et al., 1994) , and results in elevated c-Src activity (Muthuswamy et al., 1994) . Overexpression of ErbB2 has also been shown to enhance the stabilization and protein synthesis of c-Src (Tan et al., 2005) . Furthermore, pharmacological inhibition of c-Src causes a reduction in ErbB2-mediated soft agar colony formation and motility (Sheffield, 1998; Belsches-Jablonski et al., 2001) . Taken together, these studies suggest that c-Src plays an important role in ErbB2 oncogenic signaling.
Although ErbB2/c-Src interactions have been described, whether c-Src interacts with ErbB3 and/or affects ErbB2/ErbB3 complex formation and function has not been well studied. Using a C3H10T1/2 murine fibroblast model system as well as human breast cancer cells, we show that c-Src positively regulates HRGindependent and -dependent ErbB2 and ErbB3 heterocomplex formation, activation and downstream signaling, and that this ability of c-Src correlates directly with its effects on ErbB3-dependent anchorage-independent growth and motility. These studies demonstrate for the first time that c-Src plays a critical role in ErbB2-mediated oncogenic signaling by positively regulating ErbB2/ErbB3 heterocomplex formation.
Results
Characterization of C3H10T1/2 clonal cell lines overexpressing ErbB3, wt c-Src and/or K À c-Src To examine the mechanism by which c-Src modulates ErbB2 functional activity, we utilized the C3H10T1/2 murine fibroblast cell line, which naturally expresses high levels of ErbB2 (Figure 1 and data not shown), to generate stable clones that overexpress ErbB3 and either wild-type (wt) or kinase-inactive (K À ) c-Src. Figure 1 shows expression of exogenous ErbB3 (lanes 2-3, 5-6 and 8-9), wt c-Src (lanes 4-6) or K À c-Src (lanes 7-9) in the appropriate cell lines. The levels of K À c-Src were lower than those of ectopic wt c-Src (lanes 7-9 vs lanes 4-6, respectively), evidence of K À c-Src's restrictive growth properties. Interestingly, levels of ErbB3 overexpression were more variable among clones expressing K À c-Src (lanes 8-9) than among those expressing wt c-Src (lanes 5-6). For subsequent investigation, we selected clones that had comparable levels of ErbB2 and ErbB3.
The catalytic activity of c-Src is necessary for the biological activity of ErbB2/ErbB3 We first tested whether c-Src overexpression might affect ErbB2/ErbB3-dependent anchorage-independent growth or cell motility in the 10T1/2 system. Figure 2a shows that overexpression of ErbB3 alone was sufficient to induce colony formation in soft agar. However, cooverexpression of K À c-Src significantly reduced ErbB3-dependent colony formation both in the presence and absence of HRG (Po0.002). In similar studies, PP2 also inhibited ErbB3-mediated anchorage-independent growth (data not shown).
In addition, we found that the catalytic activity of c-Src was needed to promote chemotactic movement in a transwell assay. Figure 2b shows that co-overexpression of K À c-Src and ErbB3 significantly diminished migration (Pp0.02 relative to any other cell lines). Together, these results suggest that the catalytic activity of c-Src is necessary not only for ErbB3-mediated anchorage-independent growth but also for ErbB3-mediated motility. To determine whether overexpression of c-Src modulated tyrosine phosphorylation of ErbB2 and/or ErbB3, these receptors were specifically immunoprecipitated from serum-deprived, HRG-stimulated cells. Figure 3a shows that overexpression of ErbB3 resulted in detection of HRG-inducible increases in its tyrosine phosphorylation (lanes 3-4), whereas co-overexpression with wt c-Src significantly enhanced both the basal and HRG-stimulated levels of ErbB3 phosphorylation (lanes 7-8). In contrast, K À c-Src inhibited HRG-stimulated tyrosine phosphorylation of ErbB3 (lanes 11-12) to near basal, uninduced levels observed in the single ErbB3 overexpressors.
Immunoprecipitated ErbB2 was also examined for total auto-phosphorylation (pTyr) and auto-phosphorylation at tyrosine 1248 (Y1248), a site previously shown to correspond with enhanced transforming potential (Akiyama et al., 1991) . Figure 3b shows that HRGinduced increases in total ErbB2 auto-phosphorylation and specifically at Y1248 were readily detected in the wt c-Src/ErbB3 co-overexpressor (lanes 7-8), less so in the single ErbB3 overexpressor (lanes 3-4), and reduced or barely observed in the K À c-Src/ErbB3 double overexpressor (lanes 11-12) . Figure 3c shows that addition of the Src family kinase inhibitor, PP2, mimicked the inhibitory effect of K À c-Src on the cooperative phosphorylation of Y1248 by wt c-Src and ErbB3 (lanes 5-8). Together, these results demonstrate that wt c-Src cooperates with ErbB3 to promote tyrosine phosphorylation of ErbB2 and ErbB3, whereas K À c-Src or PP2 negatively affects these events.
c-Src regulates ErbB2/ErbB3 heterocomplex levels
The ability of c-Src to modulate receptor heterocomplex levels was then investigated. Figure 4 shows that heterocomplexes of ErbB2/ErbB3 were detected in the ErbB3 single overexpressor following addition of HRG when either ErbB3 (panel a) or ErbB2 (panel b) was immunoprecipitated (upper series of lanes, lanes 3-4). Co-overexpression of ErbB3 with wt c-Src enhanced ErbB2/ErbB3 association under both basal and HRGstimulated conditions (upper series, lanes 7-8). In contrast, the presence of K À c-Src reduced detection of the ErbB2/ErbB3 heterocomplex (upper series, lanes 11-12). These results suggest that c-Src regulates the levels of ErbB2/ErbB3 heterocomplexes.
Because wt c-Src and K À c-Src showed contrasting effects on ErbB2/ErbB3 heterocomplex levels, we asked whether there was a difference in their ability to interact with either receptor. Figure 4a and b show that the greatest amount of c-Src was found in ErbB2 or ErbB3 immunoprecipitates from cells that co-overexpressed 
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ErbB3 and wt c-Src (middle series, lanes 7-8), when compared with cells co-expressing endogenous c-Src (middle series, lanes 3-4) or K À c-Src (middle series, lanes 11-12), suggesting that c-Src kinase activity is required for both heterocomplex formation and association of c-Src with the heterocomplex. In support of this hypothesis, Figure 4c shows that the total amount of pTyr 416/418 (a measure of active c-Src in the chicken/ human proteins, respectively (Xu et al., 1999) ) in immunoprecipitated c-Src from the different cell lines correlated with the ability of c-Src to associate with ErbB2/ErbB3. Together, these results imply that c-Src utilizes its catalytic activity to court its own interactions with ErbB2 and/or ErbB3 as well as to promote the formation of the ErbB2/ErbB3 heterocomplex and its activation. That the c-Src inhibitor, PP2, could reverse the enhanced ErbB2/ErbB3 heterocomplex formation seen upon overexpression of wt c-Src further supported this conclusion. Figure 5a and b show that PP2 treatment reduced HRG-stimulated heterocomplex formation to B20% of the untreated sample in c-Src/ ErbB3 overexpressors and less than 1% in ErbB3-only overexpressors.
c-Src enhances downstream signals emanating from ErbB2 and ErbB3
MAP kinase (MAPK) and Akt are two downstream molecules activated by the ErbB2/ErbB3 heterocomplex, each through distinct pathways (Yarden and Sliwkowski, 2001) . Figure 5c shows that c-Src overexpression greatly enhanced basal activation of MAPK and Akt (compare lanes 1 and 5) and that PP2 treatment ablated both basal and HRG-dependent activation of these molecules (lanes 3-4 and 7-8). These results are consistent with the above finding that c-Src modulates ErbB2/ErbB3 heterocomplex formation.
We also examined whether the ErbB2/ErbB3 heterocomplex and c-Src cooperatively activated focal adhesion kinase (FAK), a 125 kDa protein involved in motility, cell adhesion and cytoskeletal rearrangements (Parsons et al., 2000) . Figure 5c , lanes 5 and 6 vs 1 and 2 show that the ErbB3/wt c-Src co-overexpressor exhibited greater levels of Y861 phosphorylation (mediated by c-Src (Abu-Ghazaleh et al., 2001)) than the ErbB3 single overexpressor (as determined by immunoblotting with a pTyr 861-specific antibody). Although addition of HRG did not significantly alter Tyr 861 phosphorylation in either cell line, PP2 reduced Tyr 861 phosphorylation in both cell lines (lanes 3-4, 7-8). These results support a role for c-Src in mediating phosphorylation of FAK that is largely independent of ErbB2/ErbB3, but that can cooperate with the heterocomplex following HRG stimulation (as evidenced by the results shown in Figure 2 ). Figure 7a , upper series, lanes 1 and 2 show that overall tyrosine phosphorylation of ErbB2 and ErbB3 (which migrate as 180-185 kDa proteins) was enhanced by HRG stimulation. PP2 treatment reduced both HRG-stimulated and basal overall tyrosine phosphorylation, as well as ErbB2-specific phospho-Tyr877 (located in the kinase domain) and ErbB3-specific phospho-Tyr 1289 (a PI-3 kinase (PI-3K) binding site) (second and fourth series of lanes, respectively).
The binding of the PI-3K p85 subunit to ErbB3 is a critically important step in ErbB2/ErbB3 signaling (Wallasch et al., 1995) . As shown in Figure 6a (middle series of ErbB2 and ErbB3 IPs), binding of PI-3K p85 to ErbB2 or ErbB3 was completely dependent on HRG stimulation and ablated or reduced by addition of PP2. Similar results were obtained from C3H10T1/2 cells (data not shown). However, as there is no PI-3K-binding site on ErbB2 (Schulze et al., 2005) , the reduced binding of PI3K p85 in the ErbB2 immune complex following PP2 treatment may be due to reduced heterocomplex formation between ErbB2 and ErbB3, less phosphorylation of ErbB3, or a combination of the two. Figure 7b shows that activation of c-Src (measured by immunoblotting with anti-pY416/8) as well as phosphorylation of Tyr 861 on FAK was reduced by PP2 treatment, without affecting phosphorylation of Tyr397, a FAK auto-phosphorylation site. Further analysis revealed that HRG-activated Shc (as assessed by levels of the slower migrating, activated forms), MAPK and Akt were also diminished by PP2 treatment (Figure 7c) . Together, these results are consistent with the idea that c-Src activity promotes heterocomplex formation of ErbB2 and ErbB3, which in turn activates downstream molecules in both mouse fibroblasts and human breast cancer cells.
Discussion
Since the first published report linking ErbB2 overexpression to a poor prognosis for breast cancer (Slamon et al., 1987) , much attention has been focused on understanding its molecular mechanisms of activation c-Src promotes ErbB2/ErbB3 receptor interactions RC Ishizawar et al and action. We focused on the possibility that c-Src enhances the oncogenic activity of the ErbB2/ErbB3 heterocomplex, as c-Src is also frequently overexpressed in breast cancer and is critical for mediating cellular proliferation by another ErbB family member, EGFR (Ishizawar and Parsons, 2004) . The results of our studies in both a murine fibroblast model and in human breast cancer cells indicate that c-Src regulates formation of the ErbB2/ErbB3 heterocomplex, thereby modulating receptor transphosphorylation, activation of downstream effectors and biological outcomes.
Although c-Src was found to be critical for 10T1/2 cell colony growth in soft agar and migration in a Boyden Chamber assay, neither overexpression of wt c-Src nor HRG stimulation translated into additive or synergistic increases in either biological assay. One reason for this outcome may be the potential masking effects of serum. Serum was required for both the migration and soft agar assays, but the biochemical analyses were performed in serum-free medium 7 HRG. Nevertheless, in all studies, the catalytic activity of c-Src was found to be consistently required for ErbB2/ErbB3 heterocomplex formation and subsequent consequences of its activation.
The mechanism by which high-level expression of wt c-Src facilitates and K À c-Src or PP2 treatment decreases the formation of the ErbB2/ErbB3 heterocomplex remains unclear. Several possibilities exist. First, c-Src may directly phosphorylate ErbB2 and/or ErbB3, which, in turn, could enhance heterocomplex formation by changing the conformation of one or both of the partners and/or recruiting other molecules. Several observations we have made suggest that phosphorylation of ErbB2 by c-Src is a likely possibility. For example, Tyr 877 of the ErbB2 receptor (which is thought to be an auto-phosphorylation site) displayed a high basal phosphorylation signal that was greatly reduced by PP2 treatment (Figure 7a) , implying that Tyr 877 may be phosphorylated by c-Src. Indeed, the corresponding site on ErbB1/EGFR, Tyr845, is phosphorylated by c-Src (Biscardi et al., 1999) and poorly phosphorylated by ErbB1/EGFR (Fan et al., 2004) . These considerations raise the possibility that Tyr 877 of ErbB2 could be phosphorylated by c-Src, with similar consequences.
A second possible mechanism of c-Src action might be its ability to directly recruit other proteins into the complex through its catalytic activity. Phosphorylation of adapter proteins (for example) by c-Src or ErbB2 may then facilitate stabilization or formation of the ErbB2/ ErbB3 heterocomplex. Our studies demonstrated that ErbB2 interacted more efficiently with wt c-Src than K À c-Src, and that ErbB3 associated only with overexpressed wt c-Src (Figure 4 and data not shown). These results suggest that c-Src may preferentially bind ErbB2 (perhaps constitutively when both molecules are overexpressed) and upon HRG treatment, the ErbB2/c-Src complex could associate with ErbB3. In any event, our findings indicate that the catalytic activity of c-Src is important for its own physical interaction with the receptors, as well as supporting inter-receptor interactions.
Alternatively, c-Src may enhance ErbB2/ErbB3 heterocomplex levels by preventing receptor downregulation. In fact, the ErbB2/ErbB3 complex has been shown to have a slower rate of internalization and a greater rate of recycling than other ErbB family heterodimers (Waterman et al., 1999) . c-Src may participate in these processes, with the net result being that greater numbers of activated ErbB2/ErbB3 heterodimers are maintained at the plasma membrane.
Finally, c-Src may regulate the cell surface expression of the newly synthesized ErbB2 or ErbB3. The importance of cell surface localization is exemplified by disruption of the ability of the ErbB2/ErbB3 complex to promote breast cancer proliferation, when cell surface expression of either receptor is impaired (Bao et al., 2003; Holbro et al., 2003) . In the fibroblast model system, we noticed that high levels of ErbB3 overexpression were more difficult to establish in the presence of K À c-Src. Therefore, K À c-Src may reduce the levels of the ErbB2/ErbB3 heterocomplex by preventing the translocation or disrupting the stability of one or both of the newly synthesized proteins.
Whereas most studies examining the development of the ErbB2/ErbB3 heterocomplex have focused on the driving potential of the extracellular ligands or the inherent recognition capabilities of the receptors themselves, we have determined that the intracellular tyrosine kinase, c-Src, is important in promoting this interaction. Thus, targeting c-Src may be an alternative or additional mechanism of disrupting the transforming potential of the ErbB2/ErbB3 heterocomplex.
Materials and methods
Cell culture and generation of stable clones Stable C3H10T1/2 murine fibroblast clones overexpressing wt c-Src and K À c-Src (A430 V) have previously been characterized (Ishizawar and Parsons, 2004) . Overexpression of ErbB3 in these cell lines was accomplished by co-transfection with pBABE-puro and pLXSN-erbB-3 expression plasmids (gifts of D Stern, Yale University) (Riese et al., 1995) and selection in 1 mg/ml G418 plus 500 mg/ml puromycin. Clonal cell lines were obtained by limiting dilution and thereafter maintained in Dulbeco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), and antibiotics. The MDA-MB-361 cell line was obtained from ATCC (Manassas, VA, USA) and grown in the Leibovitz's L-15 medium supplemented with 20% FBS. All tissue culture reagents were purchased from Gibco (Grand Island, NY, USA), except for puromycin, which was obtained from Calbiochem (San Diego, CA, USA).
Materials and antibodies HRG-b was purchased from NeoMarkers (Fremont, CA, USA) or Sigma-Aldrich (St Louis, MO, USA). PP2 was acquired from Calbiochem. Rabbit polyclonal antibodies specific for ErbB2 (SC-284) and ErbB3 (SC-285) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-pTyr antibody conjugated to horseradish peroxidase, RC20, was purchased from Transduction Laboratories (Lexington, KY, USA). Antip85 subunit of PI-3K and anti-Shc were acquired from Upstate Biotechnology (Lake Placid, NY, USA). Phosphospecific antibodies to ErbB2 (Y1248), c-Src (Y416/8) and FAK (Y861, Y397) were obtained from Biosource (Camirillo, CA, USA).
Antibodies to MAPK and Akt as well as phosphospecific antibodies to ErbB3 Y1289, ErbB2 Y877 and Akt were obtained from Cell Signaling (Danvers, MA, USA). Phospho-MAPK antibody was obtained from Sigma-Aldrich. c-Srcspecific antibodies included mAb 2-17 from Quality Biotech (Camden, NJ, USA) and mAb EC10 prepared in our laboratory. The anti-Erk1/2 antibody, B3B9, was a gift of M Weber (Reuter et al., 1995) . Rabbit polyclonal anti-FAK, BC3, was the gift of T Parsons (Kanner et al., 1990) . Protein A Sepharose beads and anti-mouse IgG conjugated to agarose were purchased from Sigma-Aldrich. Secondary antibodies conjugated to HRP were obtained from Amersham Biosciences (Little Chalfont, Buckinghamshire, England). Other chemical reagents were obtained from Sigma-Aldrich.
Immunoblotting and immunoprecipitation MDA-MB-361 cells or C3H10T1/2 stable, clonal cell lines were serum depleted for 18-24 h with or without 0.1% bovine serum albumin (BSA), respectively, and stimulated with 40 ng/ ml HRG from NeoMarker or 20 ng/ml from SigmaAldrich7PP2 for 10 min. For PP2 treatment, cells were pretreated with the indicated concentration of PP2 for 10 min prior to and following HRG stimulation. For direct immunoblotting, cells were then lysed in a modified RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.25% deoxycholate, and 1% IGEPAL), supplemented with 1 mM sodium orthovanadate, 50 mg/ml leupeptin, 1% aprotonin and/ or phosphatase inhibitor cocktail 1 from Sigma-Aldrich. Protein concentrations were determined by the BCA protein assay (Pierce, Rockford, IL, USA). The methods for immunoblotting and immunoprecipitation were described previously (Biscardi et al., 1999) .
Anchorage-independent growth
Sixty-millimeter tissue culture dishes, each containing a 3-ml base layer of 1.2% agarose (Seaplaque agarose, BioWhittaker Molecular Applications, Rockland, ME, USA) in a 1:1 volume of DMEM and 2 Â F10 with 0.5% FBS, were seeded with 1.5 Â 10 5 cells in 3 ml 0.6% agarose in a 3:1 volume of DMEM and 2 Â F10 containing 0.5% FBS740 ng/ml HRG. Colonies were fed every 3-4 days with 1 ml DMEM containing 0.5% FBS740 ng/ml HRG. Colonies were incubated for over 7 weeks and counted unstained at 10 Â magnification using a light microscope.
Cellular motility
Boyden Chambers with transwell inserts (Biocoat control inserts, 8.0 micron, Becton Dickinson, Bedford, MA, USA) were used to assess the ability of the various 10T1/2 clones to migrate. Transwell membranes facing the bottom chamber were coated in DMEM containing 20% FBS, and both sides of the transwell were blocked with 5 mg/ml BSA in PBS as described (Nguyen et al., 1998) . In all, 10 5 cells per 100 ml serum-free media were placed in the top chamber, whereas 800 ml DMEM containing 0.5% FBS740 ng/ml HRG was placed in the bottom chamber. Cells were incubated for 6 h, and then the upper surfaces of the transwells were swabbed clean and washed with PBS. Cells that migrated to the lower surfaces were fixed with 5% formaldehyde and stained with 0.1% crystal violet. Four visual fields per membrane were counted.
